Loading
companiesCompany
Viatris
Viatris is the generics and biosimilars group formed in 2020 from Mylan and Pfizer's Upjohn; in cancer care it supplies generic chemotherapies and biosimilar trastuzumab and pegfilgrastim, and Mylan's phase 3 biosimilar trials sit under its name.
Also called: MylanMylan Inc.Mylan Pharmaceuticals Inc.Mylan N.V.Upjohn
Overview
Viatris was created in November 2020 by the merger of Mylan with Upjohn, Pfizer's off-patent medicines business, and is headquartered in Pittsburgh. Its oncology footprint is generic injectable chemotherapies and biosimilars developed with Biocon, including trastuzumab (Ogivri) and pegfilgrastim (Fulphila), whose comparative phase 3 trials were run by Mylan. ClinicalTrials.gov lists Mylan as lead sponsor of those trials, which OnCo attributes to Viatris.
Headquarters
Pittsburgh, PA, US
Scorecard
All companies#87of 1244 companies, score 54
- approved products +12
- targets +2
- modalities +4
- regions +6
- registry trials +30
2 approved, 0 in phase 3, 0 earlier, 1 targets, 366 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
Founded
2020
ApprovedBiosimilar monoclonal antibody (anti-HER2)
Trastuzumab biosimilars · Ogivri, Herzuma, Kanjinti, Trazimera, Ontruzant, Hercessi
Near-identical copies of Herceptin, approved since 2017, that cut the price of HER2 treatment and widened access worldwide.
ApprovedPegylated recombinant granulocyte colony-stimulating factor
Pegfilgrastim · Neulasta
Pegfilgrastim (Neulasta) is a long-acting form of the growth factor G-CSF, given once per chemotherapy cycle to speed white cell recovery and prevent febrile neutropenia; one dose replaces about eleven daily filgrastim injections. Biosimilars have been sold since 2018 and the Onpro on-body injector delivers it automatically the day after chemotherapy; bone pain is the main side effect.
Similar pages
- CompanyOrganon & Co.
Shares Trastuzumab biosimilars, Biosimilar manufacturing and comparability, Biosimilar, Pivotal (registrational) trial.
- CompanySandoz
Shares Oral solid dose manufacturing (tablets and capsules), Biosimilar manufacturing and comparability, Pegfilgrastim, Generic sterile injectables (the 2023 platinum shortage).
- CompanyEurofarma
Shares Biosimilar manufacturing and comparability, Growth factors: G-CSF and febrile neutropenia prevention, Pegfilgrastim, Pivotal (registrational) trial.
- CompanyIntas Pharmaceuticals (Accord Healthcare)
Shares Oral solid dose manufacturing (tablets and capsules), Biosimilar manufacturing and comparability, Biosimilar, Generic sterile injectables (the 2023 platinum shortage).
- CompanyBiocon
Shares Biocon Biologics, Trastuzumab biosimilars, Biosimilar manufacturing and comparability, Biosimilar.
- CompanyDr. Reddy's Laboratories
Shares Oral solid dose manufacturing (tablets and capsules), Biosimilar manufacturing and comparability, Biosimilar, Generic sterile injectables (the 2023 platinum shortage).
- CompanyMabion
Shares Biosimilar, Pivotal (registrational) trial, Clinical trial.
- CompanyZhejiang Hisun Pharmaceutical
Shares Biosimilar, Pivotal (registrational) trial, Clinical trial.
technologies
drugs
ApprovedPegylated recombinant granulocyte colony-stimulating factor
Pegfilgrastim · Neulasta
ApprovedBiosimilar monoclonal antibody (anti-HER2)
Trastuzumab biosimilars · Ogivri, Herzuma, Kanjinti, Trazimera, Ontruzant, Hercessi